Asthma UK Centre for Applied Research, Centre for Medical Informatics, Usher Institute, The University of Edinburgh, Edinburgh, UK
National Heart & Lung Institute, Imperial College London, London, UK.
Thorax. 2021 Sep;76(9):860-866. doi: 10.1136/thoraxjnl-2020-216512. Epub 2021 Mar 29.
The impact of COVID-19 and ensuing national lockdown on asthma exacerbations is unclear.
We conducted an interrupted time-series (lockdown on 23 March 2020 as point of interruption) analysis in asthma cohort identified using a validated algorithm from a national-level primary care database, the Optimum Patient Care Database. We derived asthma exacerbation rates for every week and compared exacerbation rates in the period: January to August 2020 with a pre-COVID-19 period and January to August 2016-2019. Exacerbations were defined as asthma-related hospital attendance/admission (including accident and emergency visit), or an acute course of oral corticosteroids with evidence of respiratory review, as recorded in primary care. We used a generalised least squares modelling approach and stratified the analyses by age, sex, English region and healthcare setting.
From a database of 9 949 387 patients, there were 100 165 patients with asthma who experienced at least one exacerbation during 2016-2020. Of 278 996 exacerbation episodes, 49 938 (17.9%) required hospital visit. Comparing pre-lockdown to post-lockdown period, we observed a statistically significant reduction in the level (-0.196 episodes per person-year; p<0.001; almost 20 episodes for every 100 patients with asthma per year) of exacerbation rates across all patients. The reductions in level in stratified analyses were: 0.005-0.244 (healthcare setting, only those without hospital attendance/admission were significant), 0.210-0.277 (sex), 0.159-0.367 (age), 0.068-0.590 (region).
There has been a significant reduction in attendance to primary care for asthma exacerbations during the pandemic. This reduction was observed in all age groups, both sexes and across most regions in England.
COVID-19 及其后续的全国性封锁对哮喘发作的影响尚不清楚。
我们使用全国基层医疗数据库 Optimum Patient Care Database 中的一个经过验证的算法,对哮喘队列进行了一项中断时间序列(2020 年 3 月 23 日封锁为中断点)分析。我们为每一周计算了哮喘发作率,并比较了以下两个时期的发作率:2020 年 1 月至 8 月(COVID-19 前时期)和 2016-2019 年 1 月至 8 月。哮喘发作定义为与哮喘相关的医院就诊/入院(包括急诊就诊),或在初级保健中记录的急性口服皮质类固醇治疗并伴有呼吸道检查的病例。我们使用广义最小二乘法建模方法,并按年龄、性别、英格兰地区和医疗保健环境对分析进行分层。
在一个 9949387 名患者的数据库中,有 100165 名哮喘患者在 2016-2020 年期间至少经历过一次发作。在 278996 次发作中,有 49938 次(17.9%)需要医院就诊。与封锁前相比,我们观察到所有患者的发作率水平(每 100 名哮喘患者每年减少 0.196 次发作)有统计学显著下降(p<0.001)。在分层分析中,下降幅度为:0.005-0.244(医疗保健环境,只有那些没有医院就诊/入院的患者有显著下降),0.210-0.277(性别),0.159-0.367(年龄),0.068-0.590(地区)。
在大流行期间,哮喘发作到初级保健的就诊人数显著减少。这种减少在英格兰所有年龄组、男女和大多数地区都有观察到。